Marker Therapeutics, Inc. (MRKR) — 10-Q Filings
All 10-Q filings from Marker Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Marker Therapeutics' Losses Widen Amid R&D Spend, Cash Runway Shortens
— Nov 13, 2025 Risk: high
Marker Therapeutics, Inc. (MRKR) reported a net loss of $10,460,410 for the nine months ended September 30, 2025, a significant increase from the $6,893,691 net -
Marker Therapeutics' Losses Mount Amid R&D Surge, Cash Dwindles
— Aug 14, 2025 Risk: high
Marker Therapeutics, Inc. (MRKR) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $8,461,748, a 84.5% increase from -
Marker Therapeutics 10-Q: Equity Offering & Financial Update
— May 15, 2025 Risk: medium
Marker Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as TAPIMMUNE INC., reported on its financial status, -
Marker Therapeutics Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Marker Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporat -
Marker Therapeutics Files Q2 2024 10-Q
— Aug 14, 2024 Risk: medium
Marker Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is involved in pha -
Marker Therapeutics Q1 2024 Update
— May 15, 2024 Risk: medium
Marker Therapeutics, Inc. reported its first quarter 2024 results, ending March 31, 2024. The company's financial statements show changes in common stock and ad
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX